减肥药大热之际，诺德诺德和礼来明年恐成“输家”？

金十数据2023-12-11

根据彭博最新的Markets Live Pulse调查，减肥制药商诺和诺德(NVO.N)和礼来(LLY.N)很有可能在2024年表现落后于今年其它明星股。在对518名参与者进行的调查中，约34%的受访者认为减肥药生产商是今年的赢家，但是同时预计他们明年很可能会成为输家。相比之下，仅有31%的人不看好七大科技巨头明年的表现，其余的人则在日本股票和拉丁美洲股票之间各占一半。减肥药的成功引发了制药...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2390334403?lang=zh_CN&edition=full","thumbnail":"https://cdn-news.jin10.com/77e486d0-06c9-4a5a-bbb2-0b712808cb77.png/lite","is_english":false,"pubTime":"2023-12-11 17:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2390334403","market":"hk","top_or_hot":-1,"title":"减肥药大热之际，诺德诺德和礼来明年恐成“输家”？","media":"金十数据","content":"<div>\n<p>根据彭博最新的Markets Live Pulse调查，减肥制药商诺和诺德(NVO.N)和礼来(LLY.N)很有可能在2024年表现落后于今年其它明星股。\n在对518名参与者进行的调查中，约34%的受访者认为减肥药生产商是今年的赢家，但是同时预计他们明年很可能会成为输家。相比之下，仅有31%的人不看好七大科技巨头明年的表现，其余的人则在日本股票和拉丁美洲股票之间各占一半。\n减肥药的成功引发了制药...</p>\n\n<a href=\"https://xnews.jin10.com/webapp/details.html?id=128429&type=news&data_type=0\">网页链接</a>\n\n</div>\n","source":"xnew_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>减肥药大热之际，诺德诺德和礼来明年恐成“输家”？</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n减肥药大热之际，诺德诺德和礼来明年恐成“输家”？\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-11 17:43 北京时间&nbsp;&nbsp;&nbsp;<a href=https://xnews.jin10.com/webapp/details.html?id=128429&type=news&data_type=0><strong>金十数据</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>根据彭博最新的Markets Live Pulse调查，减肥制药商诺和诺德(NVO.N)和礼来(LLY.N)很有可能在2024年表现落后于今年其它明星股。\n在对518名参与者进行的调查中，约34%的受访者认为减肥药生产商是今年的赢家，但是同时预计他们明年很可能会成为输家。相比之下，仅有31%的人不看好七大科技巨头明年的表现，其余的人则在日本股票和拉丁美洲股票之间各占一半。\n减肥药的成功引发了制药...</p>\n\n<a href=\"https://xnews.jin10.com/webapp/details.html?id=128429&type=news&data_type=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2468319806.SGD","symbol_name":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","start_time":0,"source_url":"https://xnews.jin10.com/webapp/details.html?id=128429&type=news&data_type=0","article_id":"2390334403","we_media_id":null,"thumbnails":["https://cdn-news.jin10.com/77e486d0-06c9-4a5a-bbb2-0b712808cb77.png/lite"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2390334403","pubTimestamp":1702287827,"sourceInfo":{"source_id":"xnew_highlight","name":"金十要闻"},"weMediaInfo":null,"summary":"估值偏高、行业竞争加剧以及缺乏关键催化剂将使减肥药生产商明年股价承压。","collect":0,"end_time":0,"defaultTopTitle":"jin10.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SG9999001176.USD":"United Global Healthcare Acc USD","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4581":"高盛持仓","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4585":"ETF&股票定投概念","LU0058720904.USD":"联博国际健康护理基金A","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LLY":"礼来","BK4007":"制药","LU0097036916.USD":"贝莱德美国增长A2 USD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0882574055.USD":"富达全球健康医疗A ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0122379950.USD":"贝莱德世界健康科学A2","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4588":"碎股","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS"},"translate_title":"When diet pills are hot, Nord Nord and Lilly will become \"losers\" next year?","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"根据彭博最新的Markets Live Pulse调查，减肥制药商诺和诺德(NVO.N)和礼来(LLY.N)很有可能在2024年表现落后于今年其它明星股。\n在对518名参与者进行的调查中，约34%的受访者认为减肥药生产商是今年的赢家，但是同时预计他们明年很可能会成为输家。相比之下，仅有31%的人不看好七大科技巨头明年的表现，其余的人则在日本股票和拉丁美洲股票之间各占一半。\n减肥药的成功引发了制药行业的“淘金热”，带动诺和诺德今年成为欧洲市值最高的上市公司，礼来的股价也飙升了约60%。根据分析师的盈利预测，两家公司的估值均显着高于整个医疗保健行业。\n礼来公司和诺和诺德公司凭借其减肥药已成为知名品牌。礼来的Mounjaro第三季度营收14亿美元，第二季度营收7.97亿美元。本周发布的一份报告显示，Mounjaro的减肥速度比同类药物更快。\n而诺和诺德的Ozempic和Wegovy销售额超过48亿美元，加起来占公司本季度总销售额的很大一部分，未来几年其销售有望继续表现良好。\n减肥药的最大风险之一是来自辉瑞(PFE.N)和阿斯利康(AZN.O)等公司日益激烈的竞争。几个月来，分析师一直认为，更多的药物可能会使该行业更具竞争力并减少各自的市场份额。\n现在，辉瑞已成为该行业第一家面临重大阻力的大型制药公司。该公司在一份声明中表示，将停止开发每日两次的减肥药。辉瑞指出，在使用该药物的患者中观察到不良反应发生率很高，包括轻微的胃肠道问题。因此，至少目前来看，这意味着辉瑞将错过价值百亿美元的减肥药市场带来的机会。\n尽管如此，Jefferies分析师上周仍将诺和诺德列为2024年最不看好的四只欧洲股票之一。分析师Peter Welford表示，未来12个月，诺和诺德几乎没有什么关键催化剂，早期药物的管线完善可能已经被纳入计价。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2390334403"}